REGAINE®: Delivering confidence through clinical evidence

REGAINE® benefits from solid clinical evidence1-4

  • including randomized placebo-controlled trials1,3,4
  • results published in prestigious peer-reviewed scientific journals1-4

REGAINE® contains Minoxidil, the only topical treatment recommended for androgenetic alopecia (AGA) in both men and women, by the European Dermatology Forum in their S3 guideline.5

The majority of patients using Minoxidil have a positive beneficial response in AGA through reversal of the miniaturisation of the hair follicle.6

Minoxidil has by far the most studies meeting the high quality standards of modern evidence based medicine5,7 and the Cochrane review identifies it as the only topical treatment to show proven efficacy in female pattern hair loss.7

REGAINE® PIVOTAL TRIALS

A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.Olsen EA et al. J Am Acad Dermatol 2007; 57: 767-74.
http://www.ncbi.nlm.nih.gov/pubmed/17761356

CONCLUSION:
“We believe that [REGAINE® Foam] is an effective treatment for men with androgenetic alopecia”.

A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.

Lucky AW, et al. J Am Acad Dermatol 2004; 50:541–53.
http://www.ncbi.nlm.nih.gov/pubmed/15034503

CONCLUSION:
Application of 2% REGAINE® solution was superior to placebo for assessments of nonvellus hair counts and investigator assessment of hair growth/scalp coverage at week 48.

“With the introduction of numerous herbal remedies for hair loss, of which most have not been tested in randomized, double-blind, placebo-controlled trials, it is important to describe well-controlled trials that demonstrate the efficacy and safety of topical drugs”.

NB: 5% minoxidil is not licensed for use in women.

  • Jacobs JP et al. Int J Derm 1993; 32(10): 758-762.
  • Khandpur S et al. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 2002; 29(8): 489-498.
  • Lucky AW, et al. J Am Acad Dermatol 2004; 50:541–53.
  • Olsen EA et al. J Am Acad Dermatol 2007; 57: 767-74.
  • Blumeyer A, et al.Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology 2011;9 (Suppl 6):S1–57.
  • Washenik K: Topical Minoxidil Vehicles: Foam vs. Solution. In: Report on the Hair Regrowth live symposium, 6th World Congress for Hair Research, Australia on June 16, 2010.
  • van Zuuren EJ, et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev 2012;5:CD 007628